Ajanta Pharma Board of Directors

Get the latest insights into the leadership at Ajanta Pharma. Learn about the experienced professionals guiding the company's strategy and governance.

NamePosition
Mr. Mannalal B Agrawal Chairman
Mr. Madhusudan B Agrawal Vice Chairman
Mr. Yogesh M Agrawal Managing Director
Mr. Rajesh M Agrawal Joint Managing Director
Mr. David Rasquinha Independent Director
Ms. Medha Joshi Independent Director
Mr. Rajesh Dalal Independent Director
Ms. Simi Thapar Independent Director

Ajanta Pharma Share price

AJANTPHARM

2600.7

43.20 (1.69%)
NSE
BSE
Last updated on 4 Sep, 2025 | 15:29 IST
BUYSELL
Today's High

2617.00

Today's Low

2540.20

52 Week Low

2327.30

52 Week High

3485.00

The current prices are delayed, login to your account for live prices

Ajanta Pharma FAQs

The board at Ajanta Pharma consists of experienced professionals, including Mr. Mannalal B Agrawal , Mr. Madhusudan B Agrawal , and others, overseeing the company’s strategic and corporate governance.

Directors at Ajanta Pharma are typically nominated by the Nomination and Remuneration Committee and approved by shareholders, adhering to regulatory and governance standards. While this is the standard procedure, the exact process may differ depending on the company’s internal policies and governance framework.

As of the latest update, Mr. Mannalal B Agrawal is the current chairman at Ajanta Pharma.

Executive directors at Ajanta Pharma are involved in day-to-day operations, while non-executive directors, including independents, provide oversight and strategic input. While this distinction is generally followed, the specific responsibilities of executive and non-executive directors may vary based on the company’s organisational structure and governance practices.

Yes, Ajanta Pharma adheres to all applicable SEBI and Companies Act provisions related to board structure, diversity, and independence.

At Ajanta Pharma, board members usually serve fixed terms as outlined in the company’s charter or governance policy, commonly ranging between three to five years, with the possibility of renewal based on performance, shareholder approval, and regulatory norms.